University Of Tasmania

File(s) under permanent embargo

Regulatory Challenges of Synthetic Biology Trials and Other Highly Innovative Investigational Products

journal contribution
posted on 2023-05-18, 12:30 authored by Lisa EcksteinLisa Eckstein
While synthetic biology remains in the early stages of innovation, achieving its posited goal of improving human health will depend on future clinical trials. This article raises questions about Australia’s capacity to ensure that clinical trials involving these kinds of highly innovative investigational products have an acceptable initial and ongoing risk-benefit ratio. Particular challenges include scientific uncertainty surrounding the risks and benefits posed by highly innovative investigational products, as well as the normative nature of assessments of their likelihood and magnitude. These difficulties are compounded by a lack of substantive standards for judging the acceptability of identified trial risks in light of the trial’s potential benefits. In Australia, the Office of the Gene Technology Regulator, the Therapeutic Goods Administration, and Human Research Ethics Committees will share responsibility for assessing risks and benefits for participants in future synthetic biology clinical trials. The article argues that none of these bodies — as they currently operate — are equipped to undertake such reviews and canvasses strategies for better supporting them in this role.


Publication title

Macquarie Law Journal








Faculty of Law


Macquarie University * School of Law

Place of publication


Rights statement

Copyright unknown

Repository Status

  • Restricted

Socio-economic Objectives

Justice and the law not elsewhere classified

Usage metrics

    University Of Tasmania